{"version":"1.0","provider_name":"Merck.com","provider_url":"https:\/\/vip2-msd.com\/merckcom-migrated","author_name":"Merck.com","author_url":"https:\/\/vip2-msd.com\/merckcom-migrated","title":"Merck Completes Acquisition of Themis - Merck.com","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"m6CHBzcNj7\"><a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-themis\/\">Merck Completes Acquisition of Themis<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-themis\/embed\/#?secret=m6CHBzcNj7\" width=\"600\" height=\"338\" title=\"&#8220;Merck Completes Acquisition of Themis&#8221; &#8212; Merck.com\" data-secret=\"m6CHBzcNj7\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/vip2-msd.com\/merckcom-migrated\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Milestone Reflects Merck\u2019s Commitment to Accelerate SARS-CoV-2 Vaccine Program Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and Merck has received merger control clearance from the Austrian Federal Competition Authority. Themis is now a wholly-owned subsidiary of Merck. An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate . This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020. Themis developed a broad pipeline of vaccine candidates and immune-modulatory therapies using its innovative measles virus vector platform","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20200619005217r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"}